Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Casinoble Prioritizes Responsible Gambling: Ensuring Player Safety and Protection in South Africa

Cape Town, South Africa – 16 September 2024 – Casinoble South Africa reaffirms its commitment to responsible gambling by placing player safety and protection at the forefront of its operations. As a leading platform in the online gaming industry, Casinoble is dedicated to promoting safe gambling practices and minimizing the risks associated with problem gambling, ensuring a healthy and enjoyable gaming experience for all South African players.Responsible Gambling at Casinoble Casinoble recognizes the responsibility that comes with offering online gambling services. As such, we have

Prevas welcomes Design-People

Prevas has signed an agreement to acquire 75% of Design-People - a Danish company at the forefront of industrial and digital product design. Design-People, an award-winning industrial design company from 2005, is known as a curious design supplier and a driving force behind industrial- and digital product design. During the early innovation phase, Design-People uses a human-centered approach and design products that takes clients’ businesses to the next level. Design-People has a solid reputation and an impressive reference portfolio. With the help of a well-defined design process

Casinoble Canada Unveils Advanced Feature for Streamlined Casino Comparison

Toronto, ON, September 16, 2024 – Casinoble Canada is excited to announce the launch of a new feature designed to enhance the user experience and simplify the process of comparing online casinos. This advanced tool provides visitors with quick access to key information, allowing them to make informed decisions with ease.Innovative Casino Comparison at Your Fingertips The newly introduced feature on Casinoble Canada’s website is set to redefine how users interact with casino lists. By simply clicking a dedicated button at the end of each casino listing, visitors can instantly view a

Fortum provides expert services for the European Commission's Nuclear Decommissioning Assistance Programme

FORTUM CORPORATION PRESS RELEASE 16.9.2024 Fortum's Nuclear Services has signed a multi-year framework agreement with The Nuclear Decommissioning Assistance Programme (NDAP), which operates under the European Commission. Fortum’s role is to provide expert reviews and assessments related to the status and progress of European decommissioning programs funded by the EU, specifically the Ignalina (Lithuania), Kozloduy (Bulgaria), and Bohunice (Slovakia) decommissioning programs. The work will be carried out under specific assignments ordered by the European Commission within the framework

Recipharm’s investment enhances efficiency and speed for customers and patients

· Three new GMP Pilot Scale suites for blending, tableting and hard capsule filling · Complements existing GMP pilot scale capabilities in dry granulation and wet granulationRecipharm, a leading global pharmaceutical contract development and manufacturing organisation (CDMO), today announces a significant investment in its Oral Solid Development and Pilot Scale Centre in Zwickau, Germany. The investment includes three new GMP Pilot Scale suites for blending, tableting and hard capsule filling, which will complement the existing GMP pilot scale capabilities in dry granulation and wet

Medivir’s fostrox + Lenvima confirm promise of improved outcomes in advanced liver cancer, detailed and mature data presented at ESMO

· Mature results from Medivir’s phase 1b / 2a open label trial of fostrox + Lenvima® confirm improved outcomes in second-line advanced liver cancer with a median time to progression (TTP) of 10.9 months[1] (4.1 – 18.1). · The results showed an objective response (ORR) of 24%, and a median duration of response of 7.0 months. · Detailed safety update reinforces the ability to combine fostrox and Lenvima long-term, only 1 patient discontinuing fostrox due to adverse events. · Medivir’s fostrox (fostroxacitabine bralpamide) is the only orally-administered, liver-targeted inhibitor

#24-89 Notification of amendments to the rulebook for Nordic SME

Nordic Growth Market NGM AB (“NGM”) has conducted a review of the rulebook for Nordic SME (the “Rulebook”), resulting in the below amendments. A clean version as well as a mark-up of the new rulebook has been uploaded to NGM’s website and will come into effect on October 16, 2024.Section 1 and 2 (listing and delisting requirements) Clause 2.2.6 amendment: Clarification that share-related securities do not need to be submitted for listing if such securities are not intended to be publicly traded, e.g., warrants in an incentive program limited to key employees or the board of directors.

Stora Enso shares converted

STORA ENSO OYJ STOCK EXCHANGE RELEASE 16 September 2024 at 10:00 EESTDuring the 1 August – 31 August 2024 conversion period there were four conversions and a total of 43 A shares were converted into R shares. The shares were recorded in the Finnish trade register today, 16 September 2024, and trading in the new R shares will start on 17 September 2024.Breakdown of shares after conversion:A shares     175,880,250R shares     612,739,737Total           788,619,987Each A share and every ten R shares carry one vote. The total amount of votes after the conversion is at least 237,154,

BioStock: The future of obesity treatment - Iconovo develops intranasal semaglutide

Iconovo has initiated the development of an intranasally inhaled and reformulated version of semaglutide to treat obesity. By utilizing its inhalation-driven intranasal device, ICOone Nasal, the company aims to create a more user-friendly treatment than current semaglutide injections. The goal is to achieve preclinical proof-of-concept and enter into a licensing agreement, according to CEO Johan Wäborg in an interview with BioStock.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/the-future-of-obesity-treatment-iconovo-develops-

Norse Atlantic Airways Celebrates Sold-Out Inaugural Flight from London Gatwick to Las Vegas

Norse Atlantic Airways is proud to announce the successful inaugural on Thursday, September 12, of its direct route between London Gatwick and Las Vegas, the highly anticipated flight was sold out in both Premium and Economy cabins.The new route operates three times a week, allowing travellers a convenient schedule to explore Las Vegas’s world-class entertainment, fine dining, and attractions. The flight is served by the airline’s state-of-the-art Boeing 787 Dreamliners, ensuring passengers enjoy a comfortable and relaxing journey. With fares starting from £299* return, including taxes,

Commencement of subscription period in Curasight’s preferential rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Copenhagen, Denmark, 16 September 2024 – The subscription period in Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) rights issue of

Repurchase of Truecaller B shares in week 37, 2024

During 9 September 2024 and 13 September 2024 Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in total 130,000 own B shares (ISIN: SE0016787071), corresponding to 0.04% of outstanding capital, as part of the share buyback programme initiated by the board of directors. Since the start of the programme, in the end of May, more than 3 million B-shares has been repurchased which corresponds to 0.85% of the outstanding capital.The share buybacks form part of the share buyback programme announced by Truecaller on 28 May 2024. The share buyback programme will run between 28

Chairman of the board of Redsense Medical AB resigns - Acting chairman of the board appointed

Redsense Medical AB (publ), a leader in innovations for safety and monitoring of the vein needle in dialysis treatment, announces that board chairman Eva Walde has chosen to leave her post due to personal reasons. The board has unanimously decided to appoint board member Susanne Olauson as acting board chairman until the next ordinary general meeting, when a permanent successor will be elected. The company thanks Eva Walde for her efforts during her time as chairman and wishes her every success in her future undertakings.

Compressor distributor in the Netherlands to become part of Atlas Copco Group

Nacka, Sweden, September 16, 2024: Perslucht Wilda B.V. (“Perslucht Wilda”), a compressor distributor headquartered in Woudenberg, Netherlands, will become part of Atlas Copco Group.Perslucht Wilda, founded in 1979, provides portable air compressors, generators, light towers and small electric compressors and associated services. The company has 9 employees. “The acquisition of Perslucht Wilda provides an excellent opportunity to extend our direct network and presence with aftersales service in the Netherlands”, said Andrew Walker, Business Area President Power Technique. The purchase

Rejlers helps the Swedish Transport Administration upgrade road protection facilities in Norrbotten

Rejlers has been commissioned by the Swedish Transport Administration to be responsible for the design of new road protection facilities in Norrbotten. The project, which is an important part of the Swedish Transport Administration's work to improve traffic safety throughout Sweden, includes level crossings mainly in the municipalities of Boden and Älvsbyn.The Swedish Transport Administration currently has about 6,500 level crossings, of which 2,770 have active road protection systems, i.e. barriers and/or sound and light signals. The current technology's lifespan has been used up and to

GARO expands action program in GARO E-mobility, adapts the organization to prevailing market conditions and impairs inventories in the third quarter

GARO can see that the E-mobility market remains cautious and that its recovery is progressing more slowly than anticipated. In light of this, GARO E-mobility is expanding the action program from the spring to make additional annual savings of approximately MSEK 40, with the effects expected to be generated in the first quarter of 2025. Sales of plug-in vehicles have slowed in during 2024. This is impacting demand for charging infrastructure in the short term, even though there is still a widespread underlying need to expand destination charging. The market conditions should gradually

Gasum has opened a new gas filling station in Rauma, Finland

The station serves both passenger cars and heavy-duty vehicles. The local port and industry brings heavy-duty traffic to the Rauma region – it is now possible to reduce its emissions with biogas.Gasum's newest gas filling station in the Finnish town of Rauma has been opened to customers. The station provides both liquefied and compressed gas, which means that both passenger cars and heavy-duty vehicles can be refueled at the station. Like Gasum's other filling stations, the Rauma station only sells biogas, as the distribution of natural gas at all Gasum filling stations in Finland has

GRANGEX announces completion of Optioneering Study for the restart of operations at the Sydvaranger Mine

On 6 May 2024, GRANGEX AB (publ) (“Grangex” or “the Company”) announced the completion of the acquisition of the Sydvaranger Mining AS (“Sydvaranger”).  Sydvaranger owns an iron ore mine in Kirkenes, Northern Norway (the “Sydvaranger Mine”). GRANGEX’s stated strategy is to restart production of ultra-high-grade direct reduction magnetite concentrate at the Sydvaranger Mine and to become a leading supplier to the European and global steel industries as they undergo the current ‘green steel revolution’. Post completion of the acquisition, GRANGEX established a technical steering

The exercise price for the warrants of series 2023/2024 TO2 in Cell Impact has been determined to SEK 0.17 and the subscription period starts today.

In December 2023, Cell Impact AB (publ) (Nasdaq First North Growth Market: CI) ("Cell Impact" or the "Company") carried out a rights issue of units. One (1) unit consisted of eight (8) newly issued shares and two (2) warrants of series 2023/2024 TO2. Each warrant gives the owner the right to subscribe for one (1) new share in the Company. The exercise price for the warrants of series 2023/2024 TO2 is to be determined to 70 percent of the volume-weighted average price of the Company’s share on Nasdaq First North Growth Market during the period 2 September 2024 up to and including 13 September

The exercise price for the warrants of series 2023/2024 TO2 in Cell Impact has been determined to SEK 0.17 and the subscription period starts today.

In December 2023, Cell Impact AB (publ) (Nasdaq First North Growth Market: CI) ("Cell Impact" or the "Company") carried out a rights issue of units. One (1) unit consisted of eight (8) newly issued shares and two (2) warrants of series 2023/2024 TO2. Each warrant gives the owner the right to subscribe for one (1) new share in the Company. The exercise price for the warrants of series 2023/2024 TO2 is to be determined to 70 percent of the volume-weighted average price of the Company’s share on Nasdaq First North Growth Market during the period 2 September 2024 up to and including 13 September

Esmaeilzadeh Holding publishes net asset value as of 31 August 2024

As of 31 August 2024, the net asset value for Esmaeilzadeh Holding AB (publ) was SEK 6.60 billion (SEK 6.61 billion as of 31 July 2024), corresponding to a net asset value per share of SEK 8,403 (SEK 8,425 as of 31 July 2024).[1]  For further information, please contact: Mikael Ericson, CEO mikael.ericson@ehab.group For press related enquires, please contact: Michaela Abercrombie Simpson, Head of Communications Phone: +46 736 301 403 The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CEST on 16 September 2024.

There are no items matching the current filter
There are no more items matching the current filter
Back to top